Patellofemoral Update
Patellofemoral Update
August 05, 2019
1 min read
Save

PRP injections did not improve symptoms of patellar tendinopathy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A single injection of either leukocyte-rich platelet-rich plasma or leukocyte-poor platelet-rich plasma combined with an exercised-based rehabilitation program was not more effective than saline for patients with patellar tendinopathy, according to recently published results.

Researchers assessed 57 athletes with patellar tendinopathy for 6 months or more. They randomly assigned 19 patients to receive an injection with leukocyte-rich platelet-rich plasma (LR-PRP), 19 patients to receive leukocyte-poor PRP (LP-PRP) and 19 patients to receive saline. After patients received the injection, they had 6 weeks of supervised rehabilitation. At 6 and 12 weeks and at 6 and 12 months, outcome measures assessed included Victorian Institute of Sport Assessment (VISA-P), pain during activity and global rating of change. The primary outcome was the VISA-P at 12 weeks.

At 12 weeks, study retention was 93%. At 1 year, it was 79%.

Among the three treatment groups, no differences were seen in the mean change in VISA-P, pain or global rating of change at 12 weeks. The mean VISA-P score for the LR-PRP, LP-PRP and saline groups after 1 year for was 58, 71 and 80, respectively. The mean pain score was 4 for patients who received LR-PRP, was 2.4 for those who received LP-PRP and was 2 for those who received saline. The global rating of change for patients who received LR-PRP, LP-PRP and saline was 4.7, 5.6 and 5.7, respectively. – by Monica Jaramillo

 

Disclosures: Scott reports a grant from the American Orthopaedic Society for Sports Medicine for research expenditures. Please see the full study for a list of all other authors’ relevant financial disclosures.